We first evaluated proliferation to low dose IL-2 in specific T-cell subsets in BMMC or PBMC from patients with newly diagnosed, relapsed, or relapsed/refractory MM using CFSE-based assays. The gene discussed is IL2; the disease is Miyoshi myopathy.